Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA Big Molecule WatchOn July 24, 2026, Outlook Therapeutics, Inc.OphthalmologyRead full story pharminent July 31, 2026 (Last updated: August 3, 2026) Big Molecule Watch On July 24, 2026, Outlook Therapeutics, Inc. Ophthalmology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyoutNext: Novo setback casts doubt on a new way to treat heart disease Related Stories Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026 Regulatory Lilly plans Q1 2027 filing for obesity triple retatrutide pharminent July 23, 2026
